Syncrosome participated to the last Nordic Life Science Congress Cession

Syncrosome participated to the last Nordic Life Science Congress Cession

21 Sep Syncrosome participated to the last Nordic Life Science Congress Cession

NLS Days

Two weeks ago in Sweden, Syncrosome, your in vivo partner for preclinical studies, participated to the last edition of NLS Days.

It was 2 very interesting days spent to discuss with Nordic Companies and learn more about their business models and area of research in multiples field of activities such as Neurodegeneration, Cardiovascular Disease, Metabolic Syndrome….

We always try to start good collaboration and advice Biotech or Pharma companies about our in vivo efficacy, CNS-PK and PK services, discuss any in vitro or in vivo project requirements that they might have or just to get to know each other.

So see you in Malmo next year!

A few words about Syncrosome:

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

  • Drug Efficacy Studiesin several therapeutic areas :
    • Central Nervous Sytem,
    • Cardiovascular and Metabolic disease,
    • Respiratory,
    • Gastrointestinal field.
  • Early bioavailibility and CNS-PKon rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.

No Comments

Post A Comment